Angela Dispenzieri, MD, is a Consultant in the Division of Hematology and the Department of Internal Medicine at the Mayo Clinic, Rochester, MN. Dr Dispenzieri obtained her bachelor’s degree in biology from Massachusetts Institute of Technology, Cambridge, MA, qualifying in 1985. Dr Dispenzieri then undertook her medical training at Albert Einstein College of Medicine, New York City, NY, graduating in 1991, followed by a residency in internal medicine and fellowship in hematology/oncology at the Mayo Clinic.
Dr Dispenzieri is a member of the Society of Hematologic Oncology (SOHO), the SOHO Education Committee, and the Performance Expectations for Clinical Trialists Taskforce. Dr Dispenzieri is also the former President of the International Society of Amyloidosis, and former Treasurer of the International Society of Amyloidosis.
Speaking on plasma cell disorder diagnostic tools and therapeutics
Dr Dispenzieri’s primary research interests include the diagnosis and treatment of plasma cell disorders, specifically multiple myeloma, amyloidosis, and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Dr Dispenzieri is the Principal Investigator for various clinical trials, namely a Phase II trial (NCT02921893) exploring the use ixazomib citrate, lenalidomide, and dexamethasone for the treatment of POEMS syndrome.